AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01860625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT03437473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Description: Active Implantable Vagus Nerve Stimulation device.
Study NCT01303744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, once a day in the morning for 12 weeks
Study NCT01399008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.6 mg colchicine daily as flare prophylaxis
Study NCT01399008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg colchicine daily as flare prophylaxis
Study NCT01399008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03907033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
Study NCT01999205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity promotion
Description: A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
Study NCT01397331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
Study NCT00128765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an integrated self-management education program
Description: disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
Study NCT00128765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: regular practice nurse review (monitoring controls)
Description: protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Study NCT03907033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
Study NCT03907033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
Study NCT00945009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT01299402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soulera Herbal Blend
Description: This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
Study NCT01299402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
Study NCT02945644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: take at bedtime for 14 days
Study NCT02945644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take at bedtime for 14 days
Study NCT00945009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01057017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intervention
Study NCT03525210 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 9-valent HPV vaccine
Description: Vaccination
Study NCT03437473 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Description: Active Implantable Vagus Nerve Stimulation device.
Study NCT01072617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation via MagPro x100 device
Description: Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.~Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system.
Study NCT00030225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD
Study NCT02920515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorlin or Leuprorelin
Description: Gonadotrophin releasing hormone agonists (GnRHa)
Study NCT02920515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zhibo dihuang pills
Description: Traditional Chinese Medicine
Study NCT02920515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabu ying pills
Description: Traditional Chinese Medicine
Study NCT00030225 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care (Control)
Study NCT02051621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
Study NCT00128765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: care at initiative of the patient (usual GP care)
Description: care at initiative of the patient (usual GP care)
Study NCT00555932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
Study NCT02426931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the tip-flexible ureterorenoscope
Description: Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
Study NCT02426931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the classic flexible ureteroscope
Description: Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
Study NCT02051621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cavo-tricuspid-isthmus-ablation
Description: irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
Study NCT02051621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
Study NCT02904863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extra blood draw samples
Study NCT02054286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: THV01-1
Description: Intramuscular injection of THV01-1 (week 0)
Study NCT01397331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
Study NCT02412241 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LEF measures
Description: Patient-reported outcome measure; clinician-reported outcome measures
Study NCT02412241 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Technical measure
Description: Undergo standard CT scan
Study NCT02412241 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Technical measure
Description: Undergo standard ultrasound
Study NCT02628548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Description: 8 week cognitive training program
Study NCT03878303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0058TA
Description: 25 mg capsules
Study NCT03878303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo AC0058TA
Description: equivalent dose of investigational product
Study NCT02488993 — intervention group
Intervention type: OTHER
Intervention: Prospective Phase Rifaximin-α 550mg
Description: Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
Study NCT02488993 — intervention group
Intervention type: OTHER
Intervention: Prospective Phase No Rifaximin-α 550mg
Description: Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
Study NCT02488993 — intervention group
Intervention type: OTHER
Intervention: Retrospective Phase
Description: Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
Study NCT03755661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI&TXT4MSM
Description: brief in-person intervention followed by text messaging
Study NCT03613467 — intervention group
Intervention type: PROCEDURE
Intervention: VATS lobectomy
Description: Patients who received lobectomy by video-assisted thoracoscopic surgery
Study NCT03613467 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracotomy lobectomy
Description: Patients who received lobectomy by thoracotomy
Study NCT03869476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive diagnosis score
Description: * spleen fibrosis by elastography~* plasma cytokines levels~* mutationnal landscape by NGS~* CD34 circulating cells
Study NCT03599323 — intervention group
Intervention type: DRUG
Intervention: Clotrimazole 1% (Empecid L Cream, BAYB5097)
Description: Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
Study NCT01597024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Study
Description: Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
Study NCT01597024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI Study
Description: We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
Study NCT01566487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Quetiapine fumarate tablets 300mg
Study NCT01566487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate
Description: Quetiapine fumarate tablets 300mg
Study NCT03529110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Description: T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.
Study NCT03529110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ado-trastuzumab emtansine (T-DM1)
Description: The treatment will be in accordance with the approved label.
Study NCT00187070 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187070 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem cell transplant,
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187070 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: See Detailed Description section for details of treatment interventions.
Study NCT01057524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Chest Wall Oscillation (HFCWO)
Description: Airway clearance using the high frequency chest wall oscillator device
Study NCT01057524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual airway clearance
Description: Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
Study NCT01054521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature-controlled RF
Description: The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
Study NCT01054521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar RF
Description: The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
Study NCT02952560 — intervention group
Intervention type: OTHER
Intervention: Ultrasound scan
Description: Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
Study NCT00434356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT00434356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT00434356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Oral repeating dose
Study NCT00434356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose
Study NCT00434356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Intravenous repeating dose
Study NCT02461316 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
Study NCT03680872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bidirectional Neural Bypass System
Description: These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
Study NCT04966923 — intervention group
Intervention type: OTHER
Intervention: No intervention in this study
Description: Analyses of pathogenic variant TP53 and variants in genetic test
Study NCT03755583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Exclusive Enteral Nutrition
Description: a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.
Study NCT01547091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)
Description: -The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
Study NCT01547091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)
Description: -Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
Study NCT01547091 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UC-MSC+DMARDS
Description: The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
Study NCT03987906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom screening with Targeted Early Palliative Care (STEP)
Description: The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
Study NCT01885910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100mg
Description: Doxycycline 100mg by mouth once daily
Study NCT01885910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aczone 5% gel
Description: Aczone 5% gel twice daily
Study NCT01417364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone enanthate
Description: 100 mg. IM weekly throughout study
Study NCT01417364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Description: 100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
Study NCT01417364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected IM weekly throughout study
Study NCT02054884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: F16IL2 in combination with paclitaxel
Description: Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent.
Study NCT02054884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B: Paclitaxel
Description: Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent.
Study NCT03052556 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pap smear test and HPV test
Description: Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~* In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~* In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed